PAVmed Inc. (PAVM)
NASDAQ: PAVMHealthcareMedical DevicesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
PAVM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $21.51M
- EPS (TTM)
- -$14.20
- Dividend yield
- None
- 52-week range
- 2.60 – 28.44
- Day range
- 2.66 – 2.76
- Volume / Avg
- 3.76K / 30.34K
- Beta
- —
- Shares outstanding
- 8.00M
52-week range
PAVM stock today
On Oct 8, PAVM ended the session at $2.69, shedding $0.05 (1.82%), versus the S&P 500's 0.47% decline. Trading was light, with 3.76K shares changing hands, about 12% of the average daily volume. At this level, PAVM sits near the bottom of its 52-week range of $2.60 to $28.44: 90.5% below the high, set on Jan 21, 2026 and 3.5% above the low.
PAVM is down 59.4% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 81.1%. PAVmed has posted a net loss over the last twelve months (EPS of -$14.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PAVmed
Company profilePAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Dr. Lishan Aklog M.D.
- Headquarters
- New York, NY
- Employees
- 41
- IPO year
- 2016
- Website
- pavmed.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$36.50+1256.88%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
PAVmed peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NSPRInspireMD Inc. | 0.48 | -6.61% | $22.31M | vs PAVM |
| PMIPicard Medical Inc. | 9.68 | +3.31% | $22.64M | vs PAVM |
| MODDModular Medical Inc. | 2.66 | 0.00% | $25.26M | vs PAVM |
| BDMDBaird Medical Investment Holdings Ltd | 0.79 | 0.00% | $25.37M | vs PAVM |
| LFWDLifeward Ltd. | 6.43 | -1.08% | $18.21M | vs PAVM |
| IRIXIRIDEX Corporation | 0.898 | +2.24% | $15.77M | vs PAVM |
| ARAYAccuray Incorporated | 0.2414 | -4.74% | $28.83M | vs PAVM |
| HSCSHeartSciences Inc. | 3.04 | -12.89% | $14.73M | vs PAVM |
Indexes, lists and sector
Appears in lists
PAVmed stock FAQ
What is PAVmed's stock price today?
PAVM last traded at $2.69 as of Oct 8, 4:00 PM EDT, down 1.82% on the day. Prices are delayed at least 15 minutes.
Does PAVmed pay a dividend?
No. PAVmed does not currently pay a regular cash dividend.
Who is PAVmed's CEO?
Dr. Lishan Aklog M.D. is the chief executive officer of PAVmed Inc., which has about 41 employees.
Has PAVM ever split its stock?
Yes. The most recent PAVM stock split was a 1-for-30 split on Jan 2, 2026, one of 2 splits on record.
What is the PAVM 52-week high?
The 52-week high for PAVM is $28.44 and the 52-week low is $2.60. The stock is currently 90.5% below its high.